Smac Mimetic against Therapy Resistant Cancer
USP: 1. Orally active, monovalent IAP antagonist exhibits anti-tumor efficacy as a single agent 2. nM level target binding with nM level in vitro efficacy Colony formation Assay against chemotherapy resistant colon cancer cells 3. Oral Bioavailability 55 4. Better preclinical efficacy and bioavailability than existing Phase-II clinical trial comparators 5. Detailed molecular mechanisms deciphered for its mode of action 6. IAP antagonism is the major reason for its cytotoxic phenotype
- Innovator's Name
- Product/Technology Description
Central Drug Research Institute Lucknow CDRI
- Product Name: Smac Mimetic against Therapy Resistant Cancer
- Product Title: Gram Scale Synthesis, Cell based and Cell free Target Binding, Efficacy in xenograft models with Head to Head Comparisons, PK Studies, Complete mode of action.
- Description:
- Unique Selling Point: 1. Orally active, monovalent IAP antagonist exhibits anti-tumor efficacy as a single agent 2. nM level target binding with nM level in vitro efficacy Colony formation Assay against chemotherapy resistant colon cancer cells 3. Oral Bioavailability 55 4. Better preclinical efficacy and bioavailability than existing Phase-II clinical trial comparators 5. Detailed molecular mechanisms deciphered for its mode of action 6. IAP antagonism is the major reason for its cytotoxic phenotype
